NEW YORK--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals (OTCBB:IVPH) today announced that it acquired exclusive rights from TMRC, Co., Ltd. to develop and commercialize Tamibarotene in Europe. In December 2006, INNOVIVE acquired North American rights to Tamibarotene from TMRC. Tamibarotene, a novel synthetic retinoid drug candidate, will be evaluated in a Phase II pivotal trial in patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide. This international trial will be conducted under a Special Protocol Assessment (SPA) agreed upon between the company and the U.S. Food and Drug Administration (FDA).
